Back to Search
Start Over
Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria
- Source :
- Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid, Repisalud, Instituto de Salud Carlos III (ISCIII), Oncotarget
- Publication Year :
- 2017
- Publisher :
- Impact Journals, LLC, 2017.
-
Abstract
- // Laura Gonzalez-Calero 1 , Paula J. Martinez 1 , Marta Martin-Lorenzo 1 , Montserrat Baldan-Martin 2 , Gema Ruiz-Hurtado 3 , Fernando de la Cuesta 2 , Eva Calvo 4 , Julian Segura 3 , Juan Antonio Lopez 5 , Jesus Vazquez 5 , Maria G. Barderas 2 , Luis M. Ruilope 3 , Fernando Vivanco 1, 6 and Gloria Alvarez-Llamas 1 1 Department of Immunology, IIS-Fundacion Jimenez Diaz, REDinREN, Madrid, Spain 2 Department of Vascular Physiopathology, Hospital Nacional de Paraplejicos SESCAM, Toledo, Spain 3 Hypertension Unit, Instituto de Investigacion Imas12, Hospital Universitario 12 de Octubre, Madrid, Spain 4 Ibermutuamur, Madrid, Spain 5 Laboratory of Cardiovascular Proteomics CNIC, Madrid, Spain 6 Department of Biochemistry and Molecular Biology I, Universidad Complutense, Madrid, Spain Correspondence to: Gloria Alvarez-Llamas, email: galvarez@fjd.es Luis M. Ruilope, email: ruilope@ad-hocbox.com Keywords: exosomes, hypertension, albuminuria, renin-angiotensin system, proteomics Received: March 13, 2017 Accepted: April 20, 2017 Published: May 11, 2017 ABSTRACT Albuminuria is an indicator of cardiovascular risk and renal damage in hypertensive individuals. Chronic renin–angiotensin system (RAS) suppression facilitates blood pressure control and prevents development of new-onset-albuminuria. A significant number of patients, however, develop albuminuria despite chronic RAS blockade, and the physiopathological mechanisms are underexplored. Urinary exosomes reflect pathological changes taking place in the kidney. The objective of this work was to examine exosomal protein alterations in hypertensive patients with albuminuria in the presence of chronic RAS suppression, to find novel clues underlying its development. Patients were followed-up for three years and were classified as: a) patients with persistent normoalbuminuria; b) patients developing de novo albuminuria; and c) patients with maintained albuminuria. Exosomal protein alterations between groups were identified by isobaric tag quantitation (iTRAQ). Confirmation was approached by target analysis (SRM). In total, 487 proteins were identified with high confidence. Specifically, 48 proteins showed an altered pattern in response to hypertension and/or albuminuria. Out of them, 21 proteins interact together in three main functional clusters: glycosaminoglycan degradation, coagulation and complement system, and oxidative stress. The identified proteins constitute potential targets for drug development and may help to define therapeutic strategies to evade albuminuria progression in hypertensive patients chronically treated.
- Subjects :
- CHRONIC KIDNEY-DISEASE
Proteomics
0301 basic medicine
Oncology
Proteome
renin-angiotensin system
030204 cardiovascular system & hematology
urologic and male genital diseases
Workflow
Diabetic nephropathy
0302 clinical medicine
Tandem Mass Spectrometry
Protein Interaction Mapping
Protein Interaction Maps
Kidney
SYSTEM SUPPRESSION
EPITHELIAL-CELLS
Middle Aged
Pathophysiology
PROGNOSTIC VALUE
medicine.anatomical_structure
PROTEOMIC ANALYSIS
medicine.symptom
Research Paper
medicine.medical_specialty
hypertension
Urinary system
PEPTIDE IDENTIFICATION
exosomes
albuminuria
DIABETIC-NEPHROPATHY
03 medical and health sciences
Internal medicine
medicine
Humans
Pathological
Aged
HEPARAN-SULFATE
Glycosaminoglycan degradation
business.industry
EXTRACELLULAR VESICLES
COMPLEMENT C3
medicine.disease
Microvesicles
030104 developmental biology
ROC Curve
Immunology
Albuminuria
business
Biomarkers
Chromatography, Liquid
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....c90850327020bfa0d8901fd0326cef1e
- Full Text :
- https://doi.org/10.18632/oncotarget.17787